These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37371584)

  • 21. Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness.
    Hill MA; Jaisser F; Sowers JR
    Cardiovasc Res; 2022 Jan; 118(1):130-140. PubMed ID: 33188592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
    Sowers JR; Whaley-Connell A; Epstein M
    Ann Intern Med; 2009 Jun; 150(11):776-83. PubMed ID: 19487712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone: cardiovascular assault.
    Struthers AD
    Am Heart J; 2002 Nov; 144(5 Suppl):S2-7. PubMed ID: 12422134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone receptor antagonists: current perspectives and therapies.
    Guichard JL; Clark D; Calhoun DA; Ahmed MI
    Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
    Struthers AD; MacDonald TM
    Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone and end-organ damage.
    Brown NJ
    Curr Opin Nephrol Hypertens; 2005 May; 14(3):235-41. PubMed ID: 15821416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldosterone in vascular and metabolic dysfunction.
    Luther JM
    Curr Opin Nephrol Hypertens; 2016 Jan; 25(1):16-21. PubMed ID: 26575396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
    Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
    Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.
    Brem AS; Gong R
    Clin Sci (Lond); 2015 May; 128(9):527-35. PubMed ID: 25671776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
    Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
    Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
    Kolkhof P; Joseph A; Kintscher U
    Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management].
    Horký K
    Vnitr Lek; 2011 Dec; 57(12):1012-6. PubMed ID: 22277034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mineralocorticoid receptor antagonists and endothelial function.
    Maron BA; Leopold JA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice.
    Munkhjargal U; Fukuda D; Ganbaatar B; Suto K; Matsuura T; Ise T; Kusunose K; Yamaguchi K; Yagi S; Yamada H; Soeki T; Wakatsuki T; Sata M
    J Atheroscler Thromb; 2023 Apr; 30(4):326-334. PubMed ID: 35732424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.
    Bravo EL
    Curr Hypertens Rep; 2003 Apr; 5(2):122-5. PubMed ID: 12642011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid Receptor and Endothelial Dysfunction in Hypertension.
    Faulkner JL; Belin de Chantemèle EJ
    Curr Hypertens Rep; 2019 Sep; 21(10):78. PubMed ID: 31485760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldosterone: a risk factor for vascular disease.
    Fritsch Neves M; Schiffrin EL
    Curr Hypertens Rep; 2003 Feb; 5(1):59-65. PubMed ID: 12530937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans.
    Thum T; Schmitter K; Fleissner F; Wiebking V; Dietrich B; Widder JD; Jazbutyte V; Hahner S; Ertl G; Bauersachs J
    Eur Heart J; 2011 May; 32(10):1275-86. PubMed ID: 20926363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.